Kenneth F. Grossmann

Oncology
4805 NE Glisan St
Portland, OR 97213

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 52 publications

Addressing Biases in Analysis of Time of Infusion: NCI/SWOG Trial S1404 Among Participants With High-Risk Resectable Melanoma Who Received Adjuvant Anti-PD-1 Therapy.

Addressing Biases in Analysis of Time of Infusion: NCI/SWOG Trial S1404 Among Participants With High-Risk Resectable Melanoma Who Received Adjuvant Anti-PD-1 Therapy.

Journal: JCO oncology practice
Published: June 23, 2026

Neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: cohort A of the phase 2 SWOG S1512 trial.

Neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: cohort A of the phase 2 SWOG S1512 trial.

Journal: Nature cancer
Published: July 10, 2025

Randomized Placebo-Controlled, Biomarker-Stratified Phase Ib Microbiome Modulation in Melanoma: Impact of Antibiotic Preconditioning on Microbiome and Immunity.

Randomized Placebo-Controlled, Biomarker-Stratified Phase Ib Microbiome Modulation in Melanoma: Impact of Antibiotic Preconditioning on Microbiome and Immunity.

Journal: Cancer discovery
Published: January 12, 2024

Feasibility of personalized circulating tumor DNA detection in stage II and III melanoma.

Feasibility of personalized circulating tumor DNA detection in stage II and III melanoma.

Journal: Melanoma research
Published: April 11, 2023

Granulomatous and Sarcoid-like Immune-Related Adverse Events following CTLA4 and PD1 Blockade Adjuvant Therapy of Melanoma: A Combined Analysis of ECOG-ACRIN E1609 and SWOG S1404 Phase III Trials and a Literature Review.

Granulomatous and Sarcoid-like Immune-Related Adverse Events following CTLA4 and PD1 Blockade Adjuvant Therapy of Melanoma: A Combined Analysis of ECOG-ACRIN E1609 and SWOG S1404 Phase III Trials and a Literature Review.

Journal: Cancers
Published: March 13, 2023

Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.

Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.

Journal: The New England journal of medicine
Published: March 01, 2023

Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial.

Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial.

Journal: Nature medicine
Published: February 23, 2023

Effectiveness of Adjuvant Pembrolizumab vs High-Dose Interferon or Ipilimumab for Quality-of-Life Outcomes in Patients With Resected Melanoma: A Secondary Analysis of the SWOG S1404 Randomized Clinical Trial.

Effectiveness of Adjuvant Pembrolizumab vs High-Dose Interferon or Ipilimumab for Quality-of-Life Outcomes in Patients With Resected Melanoma: A Secondary Analysis of the SWOG S1404 Randomized Clinical Trial.

Journal: JAMA oncology
Published: November 23, 2022

Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma.

Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma.

Journal: Cancer discovery
Published: August 21, 2021

NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021.

NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: April 12, 2021

Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma.

Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma.

Journal: Journal for immunotherapy of cancer
Published: March 16, 2021

Real-world experience with elective discontinuation of PD-1 inhibitors at 1 year in patients with metastatic melanoma.

Real-world experience with elective discontinuation of PD-1 inhibitors at 1 year in patients with metastatic melanoma.

Journal: Journal for immunotherapy of cancer
Published: December 29, 2020
Showing 1-12 of 52

Last Updated: 09/26/2026